Uygur 2005.

Methods	Parallel‐group RCT
Participants	80 postmenopausal women (56 years old), married, with spontaneous menopausal status ≥ 1 year with follicle‐stimulating hormone level > 30 mIU/L and no contraindication to use of HRT, without chronic disease. Participants were not selected on the basis of sexual function or dysfunction
Interventions	Tibolone 2.5 mg/d (n = 40) 0.625 mg continuous conjugated equine oestrogen and 5 mg medroxyprogesterone acetate (CEE/MPA)/d Administered for 6 months (n = 40)
Outcomes	Vaginal dryness, pain during sexual intercourse as score at baseline and at post treatment
Notes	Sexual function measured on a non‐validated questionnaire Timing: unclear Trial location: Turkey Multi‐centre: no; single site
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	No information provided
Allocation concealment (selection bias)	Unclear risk	No information provided
Blinding of participants and personnel (performance bias) All outcomes	High risk	No blinding of participants and providers. States "not double blind"
Blinding of outcome assessment (detection bias) All outcomes	High risk	No blinding, with outcomes evaluated through a questionnaire
Incomplete outcome data (attrition bias) All outcomes	High risk	8/80 dropped out (2 from tibolone group because of bleeding, 6 from CEE/MPA group ‐ 1 for mastalgia, 1 for menorrhagia, 2 for weight gain, 2 for loss to follow‐up)
Selective reporting (reporting bias)	Unclear risk	Study protocol not available
Conflict of interest	Unclear risk	No information provided